"Ipidacrine"

EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE. To evaluate the efficacy of combination of alpha-lipoic acid and acetylcholinesterase inhibitor (ipidacrine hydrochloride) to prevent the development and improve the course of paclitaxel-induced peripheral with an acetylcholinesterase inhibitor (ipidacrine hydrochloride) significantly reduces the symptoms and severity of PIPN. The manifestations of PIPN in patients of the control group were significantly more severe compared to the group in which the study drugs were used. The average severity of neuropathy after 3 and 6 cycles was 1.75 and 2.62 in group I, and 1.12 and 1.62 - in group II, respectively (improvement by 15.75

EFFECTIVENESS OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE IN PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ASSESSED BY ELECTRONEUROMYOGRAPHY OF SUPERFICIAL PERONEAL AND SURAL NERVES. To investigate the neurofunctional parameters in breast cancer (BC) patients with paclitaxel-induced peripheral neuropathy (PIPN) and to clarify the feasibility of using alpha-lipoic acid (ALA ) in combination with the acetylcholinesterase inhibitor ipidacrine hydrochloride (IPD) for its prevention. 100 BC patients (T1-4N0-3M0-1) prescribed for polychemotherapy (PCT) by the AT (paclitaxel, doxorubicin) or ET (paclitaxel, epirubicin) regimens in the neoadjuvant, adjuvant or palliative modes, were enrolled. The patients were randomized into two groups (n = 50 per group): group I treated by PCT only

[Compression of nerves and senses: ipidacrine as the light at the end of the tunnel]. To evaluate the efficacy of the AChE inhibitor ipidacrine when added to traditional therapy in outpatients with tunnel syndromes (TS) based on clinical, neurophysiological and psycho-emotional indicators. Ninety-two patients with a verified diagnosis of TS were randomized into a main group (MG), in which ipidacrine was added to the therapy (=50), and a control group (CG), which received conventional therapy (=42). Clinical neurological examination, provocative (Tinel, Falen, Goldberg finger compression, elevator and tourniquet) tests, pain questionnaires (VAS, DN4, PainDetect, Pain Disability Index), Beck's depression scale, the Spielberger Trait and State Anxiety Inventory, electroneuromyography (ENMG

[An effect of ipidacrine (neuromidin) on electroneuromyographic parameters in the conditions of artificial decompression (a clinical/instrumental study)]. To study an effect of neuromidin on the changes in electroneuromyographic (ENMG) parameters in patients with carpal tunnel syndrome in the conditions of artificial decompression of a forearm. Sixty-four 64 patients, 46 women and 18 men, mean . There was the significant depression of the nerve function and worsening of ENMG parameters during the additional decompression as well as the aggravation of conduction block along nerve fibers (motor and sensory). In patients treated with ipidacrine, there was an increase in the amplitude of sensory and (to a less extent) of M-response that indicated the activation of axonal transport and reservation of functioning

and non-pharmacological methods) and the anticholinesterase drug ipidacrine. The second group (=21) had only basic treatment. The total duration of the study was 45 days. The effectiveness of treatment was evaluated with VAS, NDI, GROC and total duration of disability period. A battery of tests for the diagnosis of CR that included Spurling test, motor strength deficiency, ULTT, pain pattern, shoulder adduction test (diagnostic complex SPASIBO), has been developed. A positive result of all 5 tests guarantees the 94.7% accuracy of CR diagnosis. The application of ipidacrine has allowed a significant (<0.05) reduction of pain, enhancement of daily living activities and subjective improvement of well-being of patients after 1 month of treatment and mostly after 45 days. Besides, there was a considerable

attention, especially in the pre-operative stages. 56 patients have been examined to study the efficacy and safety a combination of Phenibut and Ipidacrine as an additional therapy to standard basic treatment (antihypertensive and hypoglycemic) for the correction of cognitive dysfunction in patients with comorbidity of hypertension and type 2 diabetes mellitus. Conclusions: One month after the beginning

3-(2,3,5,6,7,8-Hexahydro-1H-cyclo­penta­[b]quinolin-9-yl)-1,5-bis­(4-methoxy­phen­yl)biuret Ipidacrine (2,3,5,6,7,8-hexa-hydro-1H-cyclo-penta-[b]quinolin-9-amine) was reacted with 4-methoxy-phenyl isocyanate to give the title compound, C(28)H(30)N(4)O(4). An intra-molecular N-H⋯O hydrogen bond results in an essentially planar [r.m.s. deviation from the mean plane is 0.126 (1) Å] conformation